Milestones in the use of combined-modality radiation therapy and chemotherapy

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1173-1179

  Lawrence, Theodore S ^a   Haffty, Bruce G ^b   Harris, Jay R ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DIGESTIVE SYSTEM CANCER; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; METHODOLOGY; NEOPLASM; REVIEW;

CHEMORADIOTHERAPY; HUMANS; NEOPLASMS;

EID: 84904760138     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2281     Document Type: Article

References (80)

1. McGinn CJ, Shewach DS, Lawrence TS: Radiosensitizing nucleosides. J Natl Cancer Inst 88:1193-1203, 1996 (Pubitemid 26302032)
2. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979 (Pubitemid 9120186)
3. Spalding AC, Lawrence TS: New and emerging radiosensitizers and radioprotectors. Cancer Invest 24:444-456, 2006
4. Tarnawski R, Fowler J, Skladowski K, et al: How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 54:229-236, 2002
5. Ben-Josef E, Moughan J, Ajani JA, et al: Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 28:5061-5066, 2010
6. Tannock IF: Treatment of cancer with radiation and drugs. J Clin Oncol 14:3156-3174, 1996
7. Darby S, McGale P, Correa C, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707-1716, 2011
8. Hellman S: Stopping metastases at their source. N Engl J Med 337:996-997, 1997
9. Marks LB, Prosnitz LR: Postoperative radiotherapy for lung cancer: The breast cancer story all over again? Int J Radiat Oncol Biol Phys 48:625-627, 2000
10. Anderson SJ, Wapnir I, Dignam JJ, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27:2466-2473, 2009
11. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
12. Arvold ND, Taghian AG, Niemierko A, et al: Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885-3891, 2011
13. Recht A, Come SE, Henderson IC, et al: The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334:1356-1361, 1996 (Pubitemid 26152714)
14. Sartor CI, Peterson BL, Woolf S, et al: Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 23:30-40, 2005 (Pubitemid 41709334)
15. Pierce LJ, Hutchins LF, Green SR, et al: Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23:24-29, 2005 (Pubitemid 41702620)
16. Ahn PH, Vu HT, Lannin D, et al: Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23:17-23, 2005 (Pubitemid 41702619)
17. Harris EE, Christensen VJ, Hwang WT, et al: Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23:11-16, 2005 (Pubitemid 41702618)
18. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
19. Halyard MY, Pisansky TM, Dueck AC, et al: Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 27:2638-2644, 2009
20. Salama JK, Seiwert TY, Vokes EE: Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 25:4118-4126, 2007 (Pubitemid 47492956)
21. Tannock IF, Browman G: Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol 4:1121-1126, 1986 (Pubitemid 16059739)
22. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - MACH-NC Collaborative Group: Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949-955, 2000 (Pubitemid 30148259)
23. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
24. Brown JM, Siim BG: Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 6:22-36, 1996 (Pubitemid 26029637)
25. Overgaard J: Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Radiother Oncol 100:22-32, 2011
26. Overgaard J: Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 25:4066-4074, 2007
27. Grau C, Prakash Agarwal J, Jabeen K, et al: Radiotherapy with or without mitomycin C in the treatment of locally advanced head and neck cancer: Results of the IAEA multicentre randomised trial. Radiother Oncol 67:17-26, 2003 (Pubitemid 36570436)
28. Haffty BG, Son YH, Papac R, et al: Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J Clin Oncol 15:268-276, 1997 (Pubitemid 27020583)
29. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
30. Janssens GO, Rademakers SE, Terhaard CH, et al: Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 30:1777-1783, 2012
31. Peters L, Rischin D: Elusive goal of targeting tumor hypoxia for therapeutic gain. J Clin Oncol 30:1741-1743, 2012
32. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol 16:1310-1317, 1998 (Pubitemid 28175745)
33. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004 (Pubitemid 38580197)
34. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
35. Forastiere AA, Adelstein DJ, Manola J: Induction chemotherapy meta-analysis in head and neck cancer: Right answer, wrong question. J Clin Oncol 31:2844-2846, 2013
36. Haddad R, O'Neill A, Rabinowits G, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol 14:257-264, 2013
37. Hanna GJ, Haddad RI, Lorch JH: Induction chemotherapy for locoregionally advanced head and neck cancer: Past, present, future? Oncologist 18:288-293, 2013
38. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007 (Pubitemid 350005152)
39. Blanchard P, Bourhis J, Lacas B, et al: Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31:2854-2860, 2013
40. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
41. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003 (Pubitemid 37464533)
42. Forastiere AA, Zhang Q, Weber RS, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845-852, 2013
43. O'Sullivan B, Huang SH, Siu LL, et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31:543-550, 2013
44. Nigro ND, Vaitkevicius VK, Considine B Jr: Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum 17:354-356, 1974
45. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14:2527-2539, 1996 (Pubitemid 26300120)
46. Gunderson LL, Winter KA, Ajani JA, et al: Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/ mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344-4351, 2012
47. James RD, Glynne-Jones R, Meadows HM, et al: Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous- cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 14:516-524, 2013
48. Prolongation of the disease-free interval in surgically treated rectal carcinoma: Gastrointestinal Tumor Study Group. N Engl J Med 312:1465-1472, 1985
49. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
50. Improved survival with preoperative radiotherapy in resectable rectal cancer: Swedish Rectal Cancer Trial. N Engl J Med 336:980-987, 1997
51. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
52. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
53. Gérard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644, 2010
54. Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 27:3020-3026, 2009
55. Hofheinz RD, Wenz F, Post S, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non- inferiority, phase 3 trial. Lancet Oncol 13:579-588, 2012
56. Tepper JE, Wang AZ: Improving local control in rectal cancer: Radiation sensitizers or radiation dose? J Clin Oncol 28:1623-1624, 2010
57. Maas M, Beets-Tan RG, Lambregts DM, et al: Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633-4640, 2011
58. Iacobuzio-Donahue CA, Fu B, Yachida S, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813, 2009
59. Shewach DS, Lawrence TS: Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23:65-71, 1996 (suppl) (Pubitemid 26362198)
60. Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981 (Pubitemid 11022870)
61. Loehrer PJ Sr, Feng Y, Cardenes H, et al: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105-4112, 2011
62. Chauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592-1599, 2008
63. Ben-Josef E, Lawrence TS: Radiotherapy: The importance of local control in pancreatic cancer. Nat Rev Clin Oncol 9:9-10, 2012
64. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004 (Pubitemid 38339364)
65. Goodman KA: Quality assurance for radiotherapy: A priority for clinical trials. J Natl Cancer Inst 105:376-377, 2013
66. Ben-Josef E, Schipper M, Francis IR, et al: A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 84:1166-1171, 2012
67. Crane CH, Varadhachary GR, Yordy JS, et al: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:3037-3043, 2011
68. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
69. Martins RG, Parvathaneni U, Bauman JE, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 31:1415-1421, 2013
70. Caudell JJ, Sawrie SM, Spencer SA, et al: Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 71:676-681, 2008
71. Riaz N, Sherman EJ, Fury M, et al: Should cetuximab replace cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer? J Clin Oncol 31:287-288, 2013
72. Ang KK, Zhang QE, Rosenthal DI, et al: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:360s, 2011 (suppl; abstr 5500)
73. Morgan MA, Parsels LA, Maybaum J, et al: Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 4:1-12, 2014
74. Byfield JE, Sharp TR, Frankel SS, et al: Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 2:406-413, 1984 (Pubitemid 14075969)
75. Al-Sarraf M, Pajak TF, Cooper JS, et al: Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: A Radiation Therapy Oncology Group study. J Clin Oncol 8:1342-1351, 1990 (Pubitemid 20252306)
76. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organisation for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-2049, 1997 (Pubitemid 27209535)
77. Blackstock AW, Bernard SA, Richards F, et al: Phase I trial of twice- weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208-2212, 1999 (Pubitemid 29318854)
78. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19:3234-3243, 2001 (Pubitemid 32591441)
79. Dunst J, Reese T, Sutter T, et al: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983-3991, 2002
80. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002 (Pubitemid 34177445)